Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions
Summary
The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States. The combined entity is now poised to expand its commercialization efforts beyond Germany to France and the United Kingdom as reimbursement of digital programs continues to improve across Europe. The transaction will accelerate our mission of reaching the millions of patients suffering from these chronic conditions including through partnerships, such as our ongoing collaboration with Bayer,” said Simon Levy, CEO. We see this as a great opportunity to leverage Mahana’s unique distribution and partnership model and to expand our compelling offering in Digestive Health to the US marketplace with minimal overlap,” said Jim Mapes, CEO of HiDoc Technologies. The combined company operates across the United States, Germany, and the United Kingdom with both FDA-cleared and digital wellness programs for IBS and Tinnitus currently prescribed or offered by thousands of healthcare providers and used by tens of thousands of patients worldwide, and an exciting pipeline to reach the millions of patients suffering from IBD, Heartburn, Celiac Disease, Pruritus and Vulvodynia.
Classifications
AskAI Classifications
LabelsLinked Companies
